Relative to Cystic Fibrosis Awareness Month.
SCR 146 proclaims May 2026 as Cystic Fibrosis Awareness Month in California. The resolution is largely commemorative and educational: it describes cystic fibrosis as a serious, progressive genetic disease, highlights the prevalence of the condition and the importance of newborn screening, and notes disparities in diagnosis and access to care. It also points to recent advances in gene, mRNA, and drug therapies, and recognizes the work of the Cystic Fibrosis Research Institute in research, advocacy, education, and family support.
The resolution urges public awareness of cystic fibrosis and encourages early diagnosis, access to quality care, support for affected individuals and families, and continued research toward a cure. It does not create a regulatory program, impose mandates, or appropriate funds; instead, it serves as a formal legislative recognition and encouragement of awareness and support efforts.
As a concurrent resolution, SCR 146 does not amend the Health and Safety Code, Insurance Code, or other California statutes, and it has no direct regulatory or fiscal effect. Its legal impact is limited to officially designating May 2026 as Cystic Fibrosis Awareness Month and expressing the Legislature’s support for awareness, early screening, quality care, family support, and research. The measure primarily affects public messaging and recognition rather than rights, duties, or benefits of patients, providers, or state agencies.
The overall sentiment around the bill appears strongly supportive and noncontroversial. The Senate passed the resolution unanimously on third reading, 40-0, and the bill was chaptered without any recorded committee opposition or debate in the provided materials. The tone of the resolution is sympathetic and celebratory, emphasizing medical progress, patient needs, and the value of research and advocacy.
No notable substantive contention is reflected in the available record. Because the measure is a ceremonial awareness resolution, there is no evidence of disagreement over policy design, funding, or implementation. The only potentially sensitive issues mentioned in the text are health disparities, late or missed diagnoses due to screening limitations, and the need for expanded access to care and research, but these are presented as reasons for support rather than points of dispute.